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BACKGROUND & AIMS: Elaﬁbranor is an agonist of the perox-
isome proliferatoractivated receptor-a and peroxisome
proliferatoractivated receptor-d. Elaﬁbranor improves insulin
sensitivity, glucose homeostasis, and lipid metabolism and reduces
inﬂammation. We assessed the safety and efﬁcacy of elaﬁbranor in
an international, randomized, double-blind placebo-controlled trial
of patients with nonalcoholic steatohepatitis (NASH). METHODS:
Patients with NASH without cirrhosis were randomly assigned to
groups given elaﬁbranor 80 mg (n¼ 93), elaﬁbranor 120 mg (n¼
91), or placebo (n ¼ 92) each day for 52 weeks at sites in Europe
and the United States. Clinical and laboratory evaluations were
performed every 2 months during this 1-year period. Liver bi-
opsies were then collected and patients were assessed 3 months
later. The primary outcome was resolution of NASH without
ﬁbrosis worsening, using protocol-deﬁned and modiﬁed deﬁni-
tions. Data from the groups given the different doses of elaﬁ-
branor were compared with those from the placebo group using
step-down logistic regression, adjusting for baseline nonalco-
holic fatty liver disease activity score. RESULTS: In intention-to-
treat analysis, there was no signiﬁcant difference between the
elaﬁbranor and placebo groups in the protocol-deﬁned primary
outcome. However, NASH resolved without ﬁbrosis worsening in
a higher proportion of patients in the 120-mg elaﬁbranor group vs
the placebo group (19% vs 12%; odds ratio ¼ 2.31; 95% conﬁ-
dence interval: 1.025.24; P¼ .045), based on a post-hoc analysis
for the modiﬁed deﬁnition. In post-hoc analyses of patients with
nonalcoholic fatty liver disease activity score 4 (n ¼ 234), ela-
ﬁbranor 120 mg resolved NASH in larger proportions of patients
than placebo based on the protocol deﬁnition (20% vs 11%; odds
ratio ¼ 3.16; 95% conﬁdence interval: 1.228.13; P ¼ .018) andthe modiﬁed deﬁnitions (19% vs 9%; odds ratio ¼ 3.52; 95%
conﬁdence interval: 1.32–9.40; P ¼ .013). Patients with NASH
resolution after receiving elaﬁbranor 120 mg had reduced liver
ﬁbrosis stages compared with those without NASH resolution
(mean reduction of 0.65 ± 0.61 in responders for the primary
outcome vs an increase of 0.10 ± 0.98 in nonresponders; P <
.001). Liver enzymes, lipids, glucose proﬁles, and markers of
systemic inﬂammation were signiﬁcantly reduced in the elaﬁ-
branor 120-mg group vs the placebo group. Elaﬁbranor was
well tolerated and did not cause weight gain or cardiac events, but
did produce a mild, reversible increase in serum creatinine (effect
size vs placebo: increase of 4.31 ± 1.19 mmol/L; P < .001).
CONCLUSIONS: A post-hoc analysis of data from trial of patients
with NASH showed that elaﬁbranor (120 mg/d for 1 year)
resolved NASH without ﬁbrosis worsening, based on a modiﬁed
deﬁnition, in the intention-to-treat analysis and in patients with
moderate or severe NASH. However, the predeﬁned end point was
not met in the intention to treat population. Elaﬁbranor was well
tolerated and improved patients’ cardiometabolic risk proﬁle.
ClinicalTrials.gov number: NCT01694849.Keywords: PPARA; PPARD; NAFLD; fatty liver.
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LIVERf all chronic liver diseases, nonalcoholic steatohe-Opatitis (NASH) is of increasing concern, as it is
highly prevalent, potentially severe and without approved
therapy. NASH deﬁnes a subgroup of nonalcoholic fatty liver
disease where liver steatosis coexists with hepatic cell
injury (apoptosis and hepatocyte ballooning), and inﬂam-
mation.1 It occurs in close association with overweight/
obesity, type 2 diabetes, and cardiometabolic conditions that
deﬁne the metabolic syndrome.2 Because of the prevalence
of these comorbidities, NASH is emerging as the most
common chronic liver disease.
NASH promotes liver ﬁbrosis and some patients prog-
ress to severe hepatic diseases, including cirrhosis, liver
failure, hepatocellular carcinoma, or require liver trans-
plantation.3,4 Liver-related mortality is increased 10-fold in
NASH patients compared with the general population.5
However, NASH is also a multisystem disease that could
worsen insulin resistance, the metabolic syndrome, and the
systemic inﬂammatory state.6 Consequently, NASH patients
also have an increased rate of cardiovascular events and
neoplasia. These 2 latter conditions carry the heaviest toll in
terms of mortality, the leading cause of death being from
cardiovascular events.3,7,8
Peroxisome proliferatoractivated receptors (PPARs)
are nuclear receptors playing key roles in cellular processes
regulating metabolic homeostasis, immune-inﬂammation,
and differentiation. PPARg agonists demonstrated efﬁcacy
in improving histology in NASH,9–11 but side effects, such as
congestive heart failure, peripheral edema, bone fractures,
and weight gain severely restrict their prescription and
acceptance as long-term therapies. PPARa is most promi-
nently expressed in the liver and is activated by hypolipi-
demic ﬁbrates. PPARa controls the lipid ﬂux in the liver by
modulating fatty acid transport and b-oxidation, while
improving plasma lipids by decreasing triglycerides and
increasing high-density lipoprotein (HDL) cholesterol.12 In
addition, PPARa activation inhibits inﬂammatory genes
induced by nuclear factor-kB and decreases the expression
of acute-phase response genes.12 PPARd (also called PPARb)
regulates metabolism in liver and peripheral tissues. PPARd
agonists enhance fatty acid transport and oxidation, in-
crease HDL levels, and improve glucose homeostasis by
enhancing insulin sensitivity and inhibiting hepatic glucose
output.13 Importantly, PPARd exerts anti-inﬂammatory ac-
tivities in macrophages and Kupffer cells.14 In a pilot trial, a
selective PPARd agonist reduced liver fat content, while
improving insulin sensitivity, plasma lipids, and decreasing
g-glutamyltransferase.15
Elaﬁbranor (GFT505) is a dual PPARa/d agonist that has
demonstrated efﬁcacy in disease models of nonalcoholic
fatty liver disease (NAFLD)/NASH and liver ﬁbrosis.16 Ela-
ﬁbranor confers liver protection by acting on several path-
ways involved in NASH pathogenesis, reducing steatosis,
inﬂammation, and ﬁbrosis. In phase 2a trials in dyslipi-
demic, prediabetic and type 2 diabetic patients, elaﬁbranor
consistently improved plasma lipids and glucose homeo-
stasis, peripheral and hepatic insulin resistance, and
reduced liver inﬂammatory markers.17,18This phase II study was conducted to assess the efﬁcacy
of elaﬁbranor for NASH in an international, randomized,
placebo-controlled, multicenter, 1-year clinical trial.
Methods
Study Design
This international, multicenter, randomized placebo-
controlled study tested elaﬁbranor at the dose of 80 mg and
120 mg once a day vs placebo over 52 weeks and was con-
ducted at 56 sites, 19 in the United States and 37 in 8 Euro-
pean countries. The study had a staggered design as requested
by the regulatory agencies to test the safety of elaﬁbranor
during a 6-month period at the lower dose before exposing
patients for 1 year at the highest dose. During the ﬁrst
recruitment phase, 172 patients were screened between
September 2012 and June 2013 for treatment with 80 mg/d of
elaﬁbranor or placebo (allocation 2:1). The second recruit-
ment period at the dose of 120 mg/d started in July 2013,
when 179 patients were screened in 1 week. The randomiza-
tion of this second cohort started in October 2013 (allocation
of elaﬁbranor 120 mg or placebo in a 2:1 ratio), after unre-
stricted approval from the Independent Data and Safety
Monitoring Board. The clinical study protocol was approved in
all countries by National Authorities and Ethics Committees.
All patients gave written informed consent. All authors had
access to the study data and have approved and reviewed the
ﬁnal manuscript.
Patients
The inclusion criteria included age 18 to 75 years and a
histologic diagnosis of noncirrhotic NASH conﬁrmed by a cen-
tral pathologist. Patients were excluded if daily alcohol con-
sumption was more than 2 drink units/d (equivalent to 20 g) in
women and 3 drink units/d (30 g) in men, if steatohepatitis
was due to secondary causes, or if any other chronic liver
disease was identiﬁed.
Randomization and Masking
Randomization was obtained through a computer-
generated coding list, and treatment allocation was per-
formed centrally for all sites through a web system, based on
date of randomization, and stratiﬁed for diabetes. No stratiﬁ-
cation was made on investigation sites. Elaﬁbranor and placebo
were provided as identical capsules in wallets labeled with
code numbers. Patients, investigators, clinical site staff, and the
pathologist were masked to treatment assignment. The alloca-
tion of treatment was done in a 1:1:1 ratio for the 3 treatment
arms—placebo, elaﬁbranor 80 mg, and elaﬁbranor 120 mg.
Procedures
Patients were followed every 2 months with clinical and
laboratory evaluations throughout the 1-year treatment period.
An end-of-treatment biopsy and a 3-month post-treatment
follow-up visit were performed. Screening and end-of-
treatment biopsies were all read centrally by a single pathol-
ogist in a blinded manner (PB). At end of study, all slides
(baseline and end of study) were read in scrambled order. For
inclusion, the liver biopsy needed to be collected within the
May 2016 Elaﬁbranor RCT for NASH 1149past 9 months. Steatohepatitis was diagnosed based on the
presence of steatosis (>5% of hepatocytes), hepatocyte
ballooning, and lobular inﬂammation. Fibrosis was evaluated
using the NASH CRN ﬁbrosis staging system. Included patients
had an NAFLD activity score (NAS) ranging from 3 to 8, with at
least 1 for steatosis, ballooning, and inﬂammation. All stages of
ﬁbrosis (03) were accepted, except for cirrhosis. Noninvasive
panels for steatosis or ﬁbrosis (Fatty Liver Index, SteatoTest,
Fibrotest, and the NAFLD Fibrosis score) were measured at
baseline, 6 months, and 12 months (end of treatment). Biologic
assessments were all centralized and performed at each visit
for efﬁcacy and safety purposes.CL
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The primary outcome was reversal of NASH without
worsening of ﬁbrosis. This was deﬁned as per protocol, before
study start, as the absence (score of 0) of at least 1 of the 3
components of NASH, that is, steatosis, ballooning, and
inﬂammation; worsening of ﬁbrosis was deﬁned as the pro-
gression to bridging ﬁbrosis (ie, stage 3) or cirrhosis in patients
without bridging ﬁbrosis at baseline or to cirrhosis in patients
with bridging ﬁbrosis at baseline.
After the study was completed, a modiﬁed and more
stringent deﬁnition was proposed by academic and regulatory
experts and recommended by regulatory agencies for ongoing
trials.19,20 It deﬁnes resolution of NASH as disappearance of
ballooning (score ¼ 0), together with either disappearance of
lobular inﬂammation or the persistence of mild lobular
inﬂammation only (score ¼ 0 or 1), and resulting in an overall
pathologic diagnosis of either steatosis alone or steatosis with
mild inﬂammation; any stage increase in ﬁbrosis is considered
ﬁbrosis progression. Because this more stringent deﬁnition is
now used for current and future trials, we will here report on
both the protocol-deﬁned and the post-hoc analysis of the
modiﬁed deﬁnition.
Secondary outcomes included changes in NAS between end
of treatment and baseline biopsy (including the proportion of
patients with a 2-point decrease); changes and improvements
in individual histologic scores of steatosis, ballooning, inﬂam-
mation, and ﬁbrosis; changes in liver enzymes, in noninvasive
markers of steatosis and ﬁbrosis, in lipid and glycemic pa-
rameters, in surrogate markers of insulin resistance (fasting
insulin and Homeostasis Model Assessment Index scores);
changes in systemic inﬂammatory markers; and safety and
tolerability of elaﬁbranor at both doses.Statistical Methods
The main selection was the population of all randomized
patients that received at least one dose of study drug (inten-
tion-to-treat [ITT] sample). To assess the robustness of
ﬁndings, sensitivity analyses were performed using the per-
protocol population deﬁned as the ITT population with avail-
able liver biopsy at the end of the study. For sensitivity
purposes, the following post-hoc selections were considered:
patients with baseline NAS (bNAS) 4 (moderate or high dis-
ease activity), who are similar to those included in previous
NASH trials11,21; patients with bNAS 4 and ﬁbrosis of any
stage at baseline; patients with bNAS 4 and ﬁbrosis stage 2
at baseline (target patient population for current phase 3 tri-
als), and patients with bNAS 4 recruited in centers thatrandomized at least 1 patient in each treatment arm (justiﬁed
by the strong treatment-center imbalance). The ITT population
was the main selection and a signiﬁcant effect observed in the
ITT population was conditional to test the signiﬁcance in the
other subpopulations.
The main analysis was a mixed model featuring logistic
regression on therapy response with treatment as ﬁxed factor
(placebo, 80 mg, and 120 mg), adjusted for bNAS. The multi-
center context was accounted for by random factor. Based on
the assumption of superiority of the 120-mg dose, testing the
80-mg dose was conditional to the signiﬁcance of the effect of
120 mg (step-down testing22). No multiplicity correction was
needed due to step-down strategy.22 For patients with liver
biopsy unavailable at the end of treatment, a worst-case
imputation in assimilating missing value to therapy failure
was considered.
Post-hoc analyses tested the main treatment effect and its
interaction with baseline severity (bNAS).
For easier clinical discussion, risk ratio was reported with
odds ratio (OR) derived from logistic regression. Geometric
mean change over baseline and related t tests were used to
compare the treatment subgroups on biologic parameters,
composite biomarker scores for NAFLD and ﬁbrosis.
For sample size calculations, we assumed a 20% and 45%
responder rate in the placebo and 120-mg dose groups,
respectively, and a dropout rate of 25%. Ninety patients per
group were required to reach this difference, with a power of
80% at a 2-sided .05 signiﬁcance test level. The analyses were
conducted with the Statistical Package R (release 3.1.1), all tests
were conducted at .05 two-sided level.
Role of the Funding Source
The GOLDEN-505 study was sponsored by Genﬁt SA. The
protocol was written by a panel of academic experts and
sponsor representatives and amended in accordance to input
from regulatory bodies. The corresponding author had full
access to all the data in the study and had ﬁnal responsibility
for manuscript submission.Results
A total of 276 patients were randomized, 92 in the pla-
cebo group, 93 in the elaﬁbranor 80 mg group, and 91 in the
elaﬁbranor 120-mg group (Figure 1). Two patients did not
receive the study medication and the remaining 274 pa-
tients constitute the ITT population. Thirty-three patients
(12%) dropped out during the study (Supplementary
Table 1). Final liver biopsies were available in 237 pa-
tients (77, 82, and 78 patients in the placebo, elaﬁbranor 80
mg, and elaﬁbranor 120 mg groups, respectively). Of these,
only 5 patients were no longer diagnosed as having NASH
on the baseline biopsy upon scrambled re-reading at end of
study. This did not modify the overall results.
Table 1 shows the baseline characteristics across treat-
ment groups. The elaﬁbranor arms contained fewer Cauca-
sians, fewer men, more diabetics, and overall higher
Homeostasis Model Assessment IndexInsulin Resistance
(HOMA-IR) and insulin levels than the placebo group.
Table 2 shows the response rates and corresponding
risk ratios in the ITT population for the primary outcome.
Figure 1. Trial proﬁle. ITT,
intention to treat; PP, per
protocol.
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LIVERThere was no difference between the elaﬁbranor arms and
placebo according to the protocol-deﬁned deﬁnition. A post-
hoc analysis using the modiﬁed deﬁnition of response
shows that the response rate was signiﬁcantly higher for the
120-mg arm than for placebo (19% vs 12%; OR ¼ 2.31;
95% conﬁdence interval [CI]: 1.025.24; P ¼ .045). The
80-mg arm did not perform better than placebo for both
deﬁnitions of response, the protocol-based and the modiﬁed
deﬁnition (OR ¼ 1.48; 95% CI: 0.73.14; P ¼ .30 and 1.11,
95% CI: 0.482.57; P ¼ .80, respectively), or for any other
histologic analysis.
Results of the secondary histologic outcomes
(Supplementary Table 3) show no signiﬁcant difference
between elaﬁbranor and placebo. Nonetheless, the efﬁcacy
of the 120-mg dose to reduce the NAS by 2 points and to
improve steatosis, ballooning, and lobular inﬂammation was
more pronounced with increasing baseline severity, in
contrast to the absence of a clear pattern in the placebo or
80-mg groups.A number of post-hoc, secondary analyses were per-
formed. Importantly, there was a strong interaction effect
between baseline severity and elaﬁbranor dose, which was
signiﬁcant for 120 mg for both the protocol-deﬁned (OR ¼
2.63; 95% CI: 1.255.52; P ¼ .012) and modiﬁed deﬁni-
tion (OR ¼ 2.76; 95% CI: 1.335.76; P ¼ .007)
(Supplementary Table 2). The signiﬁcant interaction effect
with baseline severity indicated that the efﬁcacy of elaﬁ-
branor 120 mg vs placebo increased with baseline
severity. Hence, the exclusion of patients with mild disease
activity (bNAS ¼ 3, n ¼ 40) revealed a signiﬁcant direct
effect of elaﬁbranor 120 mg vs placebo (OR ¼ 3.16; 95%
CI: 1.228.13 and OR ¼ 3.52; 95% CI: 1.329.40, for the
protocol-deﬁned and modiﬁed deﬁnitions, respectively) in
the remaining population of 234 patients with bNAS 4
(85% of the ITT population); there was no signiﬁcant
difference for the 80-mg arm. Overall, the 120-mg elaﬁ-
branor dose doubled the proportion of responders vs
placebo in patients with bNAS 4.
Table 1.Baseline Characteristics of the Study Population (ITT)
Characteristic Placebo (n ¼ 92) Elaﬁbranor, 80 mg (n ¼ 93) Elaﬁbranor, 120 mg (n ¼ 89)
Demographics
Age, y, mean (SD) 52.4 (11.9) 52.7 (11.0) 52.4 (11.6)
Male, % 60 53 53
Race, Caucasian, % 92.4 94.6 79.8
BMI, kg/m2, mean (SD) 30.9 (4.2) 31.8 (5.2) 31.0 (4.4)
Weight, kg, mean (SD) 88.7 (16) 89.6 (17.8) 90.2 (15.6)
Waist circumference, cm, mean (SD) 104.7 (10.5) 106.4 (13.1) 106.3 (10.3)
Comorbidities, n (%)
Type 2 diabetes 33 (36) 37 (40) 37 (42)
Arterial hypertension 43 (47) 47 (50) 55 (62)
Hyperlipidemia 50 (54) 46 (49) 58 (65)
Cardiovascular disease 5 (5) 5 (5) 6 (7)
Concomitant medications, n (%)
Metformin 30 (32.6) 30 (32.3) 34 (38.2)
Insulin 9 (9.8) 15 (16.1) 7 (7.9)
Statins 31 (33.7) 28 (30.1) 33 (37.1)
Vitamin E 400 UI/d 0 (0) 2 (2.2) 3 (3.4)
PUFA 2 g/d 5 (5.4) 5 (5.4) 10 (11.2)
Biology, mean (SD)
ALT, U/L 63.8 (39.9) 60.7 (40.2) 63.8 (43.7)
AST, U/L 44.5 (28.6) 40.9 (27.0) 41.7 (23.8)
GGT, U/L 80.1 (102.8) 75.1 (69.0) 66.7 (65.4)
Alkaline phosphatase, U/L 76.8 (22.7) 73.8 (23.4) 77.5 (21.0)
Total bilirubin, mg/dL 10.0 (5.9) 9.6 (5.4) 10.5 (8.5)
Triglycerides, mmol/L 1.8 (1.1) 1.8 (0.9) 2.0 (1.1)
Total cholesterol, mmol/L 4.8 (1.1) 5.1 (1.2) 4.8 (1.1)
HDL cholesterol, mmol/L 1.3 (0.3) 1.3 (0.4) 1.2 (0.3)
LDL cholesterol, mmol/L 2.8 (0.9) 3.0 (1.0) 2.7 (0.9)
Fasting glucose, mmol/L 5.8 (1.5) 6.1 (2.1) 6.2 (2.1)
Fasting insulin, pmol/L 154.2 (80) 193.9 (205) 180.3 (144)
HOMA-IR 5.9 (3.9) 8.4 (10.9) 7.6 (8.1)
HbA1c, % 6.0 (0.8) 6.0 (0.9) 6.2 (1.1)
Fibrinogen, g/L 3.3 (0.6) 3.2 (0.7) 3.4 (0.8)
Haptoglobin, g/L 1.24 (0.6) 1.30 (0.5) 1.30 (0.6)
Alpha 2 macroglobulin, g/L 2.26 (0.97) 2.28 (0.82) 2.39 (0.84)
Histology, mean (SD)
Median time interval historic biopsy inclusion, d 79.4 (67.7) 110.7 (86.1) 58.2 (50.9)
NAS, n (%) 5.0 (1.3) 5.0 (1.2) 4.9 (1.3)
NAS ¼ 3 16 (17.4) 10 (10.8) 14 (15.7)
NAS 45 45 (48.9) 54 (58.0) 45 (50.6)
NAS 68 31 (33.7) 29 (31.2) 30 (33.7)
Hepatocyte ballooning 1.4 (0.5) 1.4 (0.5) 1.4 (0.5)
Lobular inﬂammation grade 1.4 (0.6) 1.4 (0.6) 1.4 (0.5)
Steatosis grade 2.2 (0.7) 2.3 (0.8) 2.2 (0.8)
Fibrosis stage, n (%) 1.5 (1.0) 1.5 (1.1) 1.7 (0.9)
0 15 (16.3) 20 (21.5) 5 (5.6)
1 32 (34.8) 28 (30.1) 39 (43.8)
2 25 (27.2) 22 (23.7) 25 (28.1)
3 (bridging ﬁbrosis) 20 (21.7) 23 (24.7) 20 (22.5)
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; GGT, g-glutamyltransferase; LDL,
low-density lipoprotein; PUFA, polyunsaturated fatty acid.
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RAs patient recruitment was based on a wide spectrum of
baseline severity (NAS 38 and ﬁbrosis stage 03), we
performed post-hoc analyses in NAS 4 populations with
increasing ﬁbrosis stages (Table 3). The response rates of
120 mg elaﬁbranor for the protocol-deﬁned deﬁnition were
signiﬁcantly higher than that of placebo, while there was no
signiﬁcant difference for the 80-mg arm. The 120-mg dosewas also more effective in the subpopulation of patients
with any ﬁbrosis (F1F3), as well as in those with moderate
or advanced ﬁbrosis (F2F3) (Table 3). The results were
qualitatively similar when using the modiﬁed deﬁnition
(data not shown).
Because of a heterogeneous center effect and the un-
balanced treatment-center distribution (due to the
Table 2.Response Rates and Main Analyses According to Protocol-Deﬁned and the Modiﬁed Deﬁnitions of Response
NAS n Placebo, n (%)
Elaﬁbranor
80 mg, n (%)
Elaﬁbranor
120 mg, n (%) OR (95% CI)a P valuea
Protocol-deﬁned primary outcome
Total 274 92 (17) 93 (23) 89 (21) 1.53 (0.703.34) .280
NAS 4 (moderate and severe) 234 76 (11) 83 (20) 75 (20) 3.16 (1.228.13) .018
NAS 3 (mild) 40 16 (50) 10 (40) 14 (29)
Modiﬁed deﬁnition of response
Total 274 92 (12) 93 (13) 89 (19) 2.31 (1.025.24) .045
NAS 4 (moderate and severe) 234 76 (9) 83 (13) 75 (19) 3.52 (1.329.40) .013
NAS 3 (mild) 40 16 (25) 10 (10) 14 (21)
aElaﬁbranor 120 mg vs placebo, direct treatment effect.
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LIVERstaggered design and an unexpected high rate of recruit-
ment), we performed an analysis in the subset of bNAS 4
patients recruited in centers that randomized at least 1
patient in each treatment arm (n ¼ 120, Supplementary
Table 4). The response rates were 29% and 26% (proto-
col-deﬁned and modiﬁed deﬁnitions) vs 5% placebo (P ¼
.01 and.02, respectively). Forty-eight percent of patients
improved the NAS by 2 points (vs 21% in the placebo arm;
P ¼ .013). Hepatocyte ballooning and lobular inﬂammation
were also signiﬁcantly improved, with a trend toward
improvement in steatosis but not ﬁbrosis.
Finally, we tested whether patients that achieved reso-
lution of NASH without worsening of ﬁbrosis in the 120-mg
elaﬁbranor arm also experienced improvement in ﬁbrosis.
Supplementary Figure 1 shows strong reductions in ﬁbrosis,
hepatocyte ballooning, and the NAS (all P < .001), as well as
in lobular inﬂammation and steatosis (both P < .05), when
compared with nonresponders to the same regimen. These
ﬁndings were similar with both deﬁnitions of response.
Patients treated with both elaﬁbranor doses (80 mg and
120 mg) improved liver function tests (alanine amino-
transferase, g-glutamyltransferase, and alkaline phospha-
tase; Figure 2AC) and lipid parameters (triglycerides,
low-density lipoprotein cholesterol, HDL cholesterol,
Figure 2DF). In diabetic patients (40% of the Intention to
Treat population), elaﬁbranor improved fasting serumTable 3.Response Rate and Main Analyses for the Modiﬁed De
Stages of Fibrosis at Baseline
Population Selection, n
Tre
Placebo Elaﬁbra
All NAS 4 234b 76 (9) 8
202c 63 (11) 7
NAS 4 with ﬁbrosis (any stage) 204b 66 (11) 6
176c 55 (13) 5
NAS 4 with moderate/advanced
ﬁbrosis (F2, F3)
118b 41 (7) 3
99c 32 (9) 3
a120 mg elaﬁbranor vs placebo, direct treatment effect.
bAll patients.
cPatients with end of trial liver biopsy.glucose (0.98 ± 0.56 mmol/L for 120 mg vs placebo; P ¼
.08) and HbA1c (0.46% for 120 mg vs placebo; P ¼ .038),
as well as markers of insulin resistance (fasting insulin,
HOMA-IR, and circulating free fatty acids, Figure 3). There
was a clear reduction in systemic inﬂammatory markers,
such as high-sensitivity C-reactive protein (42% for 120
mg vs placebo; P ¼ .161), ﬁbrinogen, and haptoglobin at
both doses (Supplementary Figure 2A). In line with the
histologic changes, serum panel biomarkers of steatosis and
ﬁbrosis, such as SteatoTest, Fatty Liver Index, Fibrotest/
FibroSure, and the NAFLD Fibrosis score, showed signiﬁcant
reductions in patients treated with elaﬁbranor 120 mg
compared with placebo (Supplementary Figure 2B).
Elaﬁbranor was safe and well tolerated. Clinical adverse
events were mostly mild and similar in the placebo and
elaﬁbranor arms (Table 4). There were no cardiovascular
events or deaths in the elaﬁbranor arms. Six patients (6.5%)
were discontinued for adverse events in the placebo group, 7
(7.9%) in the 80-mg group, and 5 (5.4%) in the 120-mg
groups. There was a mild, reversible but statistically signiﬁ-
cant increase in serum creatinine (effect size vs placebo: 4.31
± 1.19 mmol/L; P < .001). Other renal markers, such as
cystatin C and microalbuminuria, remained normal. The in-
crease in creatinine led to a reported renal impairment/
failure in 7 patients treated with elaﬁbranor (Supplementary
Table 5). All of them had increased creatinine at baseline; 1ﬁnition of Response in Patients With bNAS 4 and Various
atment arm, n (%)
OR (95% CI)a P valueanor 80 mg Elaﬁbranor 120 mg
3 (13) 75 (19) 3.52 (1.329.40) .013
2 (15) 67 (21) 3.26 (1.179.02) .024
7 (15) 71 (20) 3.75 (1.3910.12) .009
8 (17) 63 (22) 3.22 (1.158.99) .026
9 (10) 38 (13) 18.46 (4.8070.96) .0001
3 (12) 34 (15) 10.59 (2.5244.50) .002
Figure 2. Changes from baseline in liver enzymes (AC) and plasma lipids (DF) in treatment groups of the Per Protocol set
(n ¼ 237). Results are expressed in mean values of changes from baseline during treatment with placebo (n ¼ 77), elaﬁbranor
80 mg (n ¼ 82) and elaﬁbranor 120 mg (n ¼ 78). Error bars represent 95% CIs. ALT, alanine aminotransferase (A); Gamma-GT,
g-glutamyltranspeptidase (B). LDL, low-density lipoprotein.
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Rof them had signiﬁcant pre-existing increases in creatinine,
cystatin C, urinary neutrophil gelatinase-associated lipocalin,
urinary creatinine, serum albumin, and urinary albumin; and
decreased creatinine clearance, and was therefore dis-
continued. Weight did not change and there was no signiﬁ-
cant reduction in hematocrit or hemoglobin vs placebo.Serious adverse events occurred in 11 patients in the placebo
(12%), 15 patients in the 80-mg (16.1%), and 14 patients in
the 120-mg (15.8%) arms. Treatment-related serious
adverse events occurred in 2 patients in the 80-mg elaﬁ-
branor arm (spontaneous abortion, ataxia, fasciculation, and
tremor), in 2 patients in the elaﬁbranor 120 mg arm (acute
Figure 3. Elaﬁbranor-
induced changes in
glucose homeostasis
markers in type 2 diabetic
patients. Type 2 diabetic
patients account for 40%
of the ITT population (n ¼
94). Mean changes vs
baseline in elaﬁbranor 80
mg (n¼ 31) and elaﬁbranor
120 mg (n ¼ 35) groups
were compared with the
changes in placebo group
using a mixed model with
group as ﬁxed factor and
baseline value as a covar-
iate. The effect size
compared with placebo
was calculated and
expressed as LSMean.
Error bars represent 95%
CIs. #P < .05 vs placebo;
##P < .01 vs placebo. FFA,
free fatty acids; FPG, fast-
ing plasma glucose.
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LIVERpancreatitis, Parkinson disease), and in 4 patients from the
placebo arm (renal cancer, breast cancer, bladder cancer, and
pancreatic cancer).
Neoplastic serious adverse events were reported in 6
patients during the study and the 3-month follow-up
periods: one bladder cancer in the elaﬁbranor 80-mg arm
(unlikely related to study drug) in a patient with previous
doubtful cytologic lesions, and 5 cancers in the placebo arm
(the 4 described above and 1 esophageal cancer considered
unlikely related to study drug).Discussion
This randomized controlled trial provides evidence of
efﬁcacy of the dual PPARa/d activator elaﬁbranor on both
histologic reversal of NASH and metabolic improvement in
patients with NASH. Both are important objectives on the
path of controlling NASH. Steatohepatitis is indirectly
associated with reduced hepatic survival in NAFLD.5,23 It
drives ﬁbrogenesis, a slow process of hepatic scar formation
that can result in cirrhosis and its deadly complications,
such as liver failure, portal hypertension, and hepatocellular
Table 4.Most Frequent Reported Treatment-Related Adverse Events
Adverse event
Elaﬁbranor, 80 mg, n (%)
(n ¼ 93)
Elaﬁbranor, 120 mg, n (%)
(n ¼ 89)
Placebo, n (%)
(n ¼ 92)
Total
(n ¼ 274)
Nausea 13 (13.98) 9 (10.11) 9 (9.78) 31 (11.31)
Headache 6 (6.45) 7 (7.87) 8 (8.7) 21 (7.66)
Diarrhea 6 (6.45) 5 (5.62) 4 (4.35) 15 (5.47)
Fatigue 5 (5.38) 5 (5.62) 4 (4.35) 14 (5.11)
Asthenia 4 (4.3) 0 (0) 2 (2.17) 6 (2.19)
Renal failurea 1 (1.08) 4 (4.49) 0 (0) 5 (1.82)
Renal impairment a 0 (0) 2 (2.25) 0 (0) 2 (0.73)
Abdominal pain 0 (0) 5 (5.62) 6 (6.52) 11 (4.01)
Abdominal pain, upper 1 (1.08) 3 (3.37) 3 (3.26) 7 (2.55)
Vomiting 5 (5.38) 3 (3.37) 2 (2.17) 10 (3.65)
Myalgia 5 (5.38) 2 (2.25) 2 (2.17) 9 (3.28)
Decreased appetite 3 (3.23) 5 (5.62) 0 (0) 8 (2.92)
Rash 3 (3.23) 4 (4.49) 1 (1.09) 8 (2.92)
Pruritus 1 (1.08) 1 (1.12) 2 (2.17) 4 (1.46)
aTerm of adverse event as reported by the investigator, not based on any speciﬁc deﬁnition.
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Rcarcinoma. Consequently, clearance of steatohepatitis,24 that
is, reversal to a normal liver or to steatosis without
steatohepatitis—a condition not associated with increased
hepatic morbidity or mortality—is expected to improve
hepatic prognosis and is now accepted as the best, short-
term surrogate for histologic improvement in NASH
trials.25,26
When analyzed according to the a priori, protocol-
deﬁned primary outcome, there were no signiﬁcant dif-
ferences in treatment response between the 2 elaﬁbranor
groups and placebo. However, when using an updated,
modiﬁed deﬁnition of reversal of NASH without worsening
of ﬁbrosis,19,20 the 120-mg elaﬁbranor arm performed
signiﬁcantly better than placebo in the ITT population. The
latter deﬁnition is more stringent than the one used in the
protocol. First, it emphasizes hepatocyte ballooning, a sign
of liver-cell injury and a cardinal feature of steatohepatitis
that is associated with disease progression and enhanced
ﬁbrogenesis. In contrast, the protocol-based deﬁnition
required the disappearance of either steatosis, inﬂamma-
tion, or hepatocyte ballooning. Second, based on older data
showing that bridging ﬁbrosis but not earlier stages is
associated with liver-related mortality,23,27–29 only pro-
gression to bridging ﬁbrosis (or to cirrhosis) was consid-
ered “worsening of ﬁbrosis” in the protocol-based
deﬁnition. Instead, the modiﬁed deﬁnition deﬁnes wors-
ening of ﬁbrosis as any one-stage increase based on recent
data showing that even early ﬁbrosis is associated with
global and liver-related mortality.7 Importantly, this more
stringent deﬁnition led to a lower placebo effect. Earlier
studies have not explicitly deﬁned reversal of NASH and
subtle differences in the criteria used might explain the
variable rates of response in the placebo group (from
13%21 to 21%11). Therapeutics in NASH is an evolving ﬁeld
and previous trials have used an aggregate histologic score,
the NAS, as a primary end point.11,21 However, the prog-
nostic value of the NAS is not established.7,23,30 We expect
that future, large phase 3 trials will be using this morestringent deﬁnition of response and, therefore, we reported
on both deﬁnitions of primary response in an attempt to
facilitate comparisons of the magnitude of the effect both
across trials and across classes of pharmacologic agents.
Interestingly, for both deﬁnitions there was a signiﬁcant
interaction effect with baseline activity, suggesting that the
latter is an important determinant of the efﬁcacy of
elaﬁbranor.
Regardless of the deﬁnition of response, elaﬁbranor at
120 mg was signiﬁcantly superior to placebo in the post-hoc
analysis after excluding the 15% of patients with mild
steatohepatitis (ie, bNAS of 3). The 80-mg dose was not
signiﬁcantly better than placebo in any primary or second-
ary histologic analyses. Patients with mild but well-deﬁned
NASH were allowed to participate because of early concerns
about recruitment feasibility, and because it was assumed
that resolution of NASH was dependent on the presence of
NASH and not on a particular level of severity. In these
patients with mild steatohepatitis, there was an unexpect-
edly high placebo response rate that might have led to a lack
of treatment effect in the planned primary outcome
assessment. In addition, the observation that elaﬁbranor is
more efﬁcient in more severe disease is consistent with
recent data showing that hepatic PPARa expression is
reduced in advanced inﬂammatory and ﬁbrotic NASH and
that resolution of NASH is associated with a recovery of
PPARa expression.31 Whatever the explanation for the fail-
ure of elaﬁbranor to signiﬁcantly outperform placebo in
patients with mild disease, it is important to note that these
patients are usually not considered eligible for pharmaco-
logic therapy, but rather should be managed through dietary
and lifestyle changes. The 2 previous large trials in NASH
that had NAS reduction as a primary outcome, only included
patients with an NAS 4,11,21 and current practice for drug
development is to include only patients with moderate or
severe disease, deﬁned by a NAS 4. Similarly, it has been
shown that ﬁbrosis is a strong predictor of liver-related
deaths7 and patients with ﬁbrosis are at highest need for
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LIVERpharmacotherapy. In secondary analyses of patients with
moderate or severe NASH, 120 mg elaﬁbranor was better
than placebo, regardless of the presence or severity of
ﬁbrosis. The histologic beneﬁt of the 120-mg dose was
mirrored by a signiﬁcant improvement in liver function
tests, in particular alanine aminotransferase, g-glutamyl-
transferase, and alkaline phosphatase, and in noninvasive
serum panels of steatosis (Steatotest, Fatty Liver Index) and
ﬁbrosis (NAFLD Fibrosis score and Fibrotest), which are
likely more sensitive and earlier response indicators than
histology.
In order to randomize 270 patients, 56 sites were
selected, with competitive recruitment and centralized
randomization. Due to the unexpectedly high recruitment
rates and the staggered design, treatment distribution
across the sites was imbalanced. Patient recruitment ranged
from 1 to 24 randomized patients per site, and only 15 sites
had patients randomized in all 3 treatment arms. In an
exploratory, post-hoc analysis designed to control for both
center effect and baseline severity, the efﬁcacy of 120 mg
elaﬁbranor was explored in the subset of patients with
bNAS 4 from centers that randomized at least 1 patient
per treatment arm. Both NASH resolution and a reduction
by 2 points in the NAS were achieved more often than
placebo. Interestingly, the 21% response rate of the placebo
arm for a 2-point NAS reduction is comparable to previous
studies,11,21 thus suggesting that this subgroup of the pop-
ulation is representative of patients included in previous
trials.
Because prevention of the occurrence of cirrhosis is the
ultimate goal, both from a clinical and a regulatory stand-
point,26 drug therapies for NASH should ideally impede
ﬁbrogenesis, either directly or indirectly, as a consequence
of clearing steatohepatitis. Fibrosis reduction has been an
elusive goal so far,11,32 but recently, a randomized trial of
obeticholic acid reported a reduction in ﬁbrosis stage over
18 months of therapy in NASH patients.21 The GOLDEN-
505 trial was shorter and not designed for anti-ﬁbrotic
end points. It provided the proof-of-principle that resolu-
tion of steatohepatitis can result in improvement of
ﬁbrosis, an indirect anti-ﬁbrotic effect. Responders for the
primary end point, at the 120-mg elaﬁbranor dose, expe-
rienced a signiﬁcant reduction in ﬁbrosis, which was not
seen in the overall group of treated patients. Whether a
direct anti-ﬁbrotic potency of elaﬁbranor, reported in
experimental murine models of ﬁbrosis,16 can be repro-
duced in humans deserves speciﬁc testing in longer trials.
Future phase 3 trials will evaluate the effect of elaﬁbranor
on the rate of progression to cirrhosis as a result of the
resolution of NASH or also through a direct anti-ﬁbrotic
effect.
An equally important aspect when treating patients with
NASH is the requirement for absence of deterioration (or at
best improvement) of the cardiometabolic comorbidities
that contribute to overall mortality.25,26 In addition, insulin
resistance, an almost constant feature of NASH, could be
causally related to the hepatic buildup of fat, induction of
lipotoxic compounds within the liver, and systemic and
adipose tissue inﬂammation. All of these pathwayscontribute to liver injury and ﬁbrosis and, therefore,
improving insulin sensitivity could also have beneﬁcial
effects on hepatic damage, as trials of pioglitazone have
shown.9–11 As expected from earlier phase 2 studies,17,18
including a hyperinsulinemiceuglycemic clamp study in
insulin-resistant patients, elaﬁbranor improved markers of
insulin resistance, such as the HOMA-IR index, hyper-
insulinemia, and free fatty acids, and also signiﬁcantly
reduced HbA1c in diabetics, which reﬂects improved gly-
cemic control. The pro-atherogenic lipid proﬁle of NASH
patients was also improved with signiﬁcant reductions of
total and low-density lipoprotein cholesterol, and increases
in HDL cholesterol at both elaﬁbranor doses. Remarkably,
the improvements in glycemic and lipid parameters were
achieved in patients already treated with conventional
glucose and lipid-lowering therapies, which suggests an
additional, direct effect of PPARa/d agonism. It is interesting
to note that contrary to placebo-induced resolution of NASH,
patients that met the primary end point on elaﬁbranor also
exhibited a greater degree of improvement of metabolic and
inﬂammatory parameters than nonresponders. The tempo-
ral interaction and dose dependency between the metabolic
effects and the histologic response of elaﬁbranor remains to
be elucidated in larger trials.
Elaﬁbranor showed a very good tolerability and safety
proﬁle throughout the 1-year exposure in this trial. This is
of paramount importance, as NASH therapies are expected
to be taken on a long-term basis. In addition, these patients
often have asymptomatic liver disease and are therefore
less willing to tolerate drug-induced side effects in the long
term. There was a mild, isolated, and reversible increase in
creatinine levels in some patients, and longer post-
treatment follow-up is necessary to conﬁrm the revers-
ibility of this biologic effect. PPARa agonists, such as
fenoﬁbrate, are known to induce reversible increases in
serum creatinine without promoting renal failure, as a
result of a pharmacodynamic effect.33–35 The mechanisms
are not entirely known, but might involve increased skel-
etal muscle production. An improvement in renal function
upon ﬁbrate treatment has been reported in a meta-anal-
ysis36 that described a reduction in albuminuria progres-
sion. Here, the increase in creatinine was lower than that
observed with fenoﬁbrate (7.1% with 120 mg elaﬁbranor
vs 17.2% with fenoﬁbrate; a >20% increase in half of the
treated population from the ACCORD [Action to Control
Cardiovascular Risk in Diabetes] trial34). However, the
absence of an adverse effect of elaﬁbranor on renal func-
tion in patients with NASH should be conﬁrmed in larger
trials.
This trial has several other strengths and some limita-
tions. The rigorous centralized pathologic reading for both
inclusion and end-of-treatment biopsies avoided inclusion
of patients without clearly deﬁned NASH,24 and provided
uniformity and lack of inter-observer variability for the
assessment of histologic end points. The proportion of
screen failures for histology was low, thus ensuring that
included patients were representative of most real-life
NASH patients seen in tertiary centers. Likewise, the low
proportion of missing end-of-treatment biopsies minimized
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that this was the ﬁrst large, international, multicenter
trial in NASH. However, there were also methodologic lim-
itations. The staggered design of the trial could have
resulted in unequal access to the 3 treatment arms, as the
randomization sequence was not set upfront for the 3 arms.
The competitive recruitment resulted in a variable number
of included patients in each center and in an uneven dis-
tribution between treatment arms that contributed to a
signiﬁcant center effect. Finally, the inclusion of patients
with mild steatohepatitis (bNAS 3) might have blunted the
effect of elaﬁbranor in the overall ITT population, as it
resulted in a high placebo response rate. Nonetheless, the
size of the trial allowed exploratory subgroup analyses that
strengthened the demonstration of efﬁcacy. Although sec-
ondary analyses are to be considered with caution, this was
not a registration, phase 3 trial, but a proof-of-concept,
phase 2b exploratory trial designed to inform the design
of subsequent, larger, pivotal studies.
The results of this trial compare favorably with results of
other investigational agents tested in comparable trials. For
instance in the FLINT (Farnesoid X Receptor (FXR) Ligand
Obeticholic Acid in NASH Treatment) trial, obeticholic acid
induced resolution of NASH in 22% of patients vs 13% in
the placebo group. The difference became signiﬁcant in a
post-hoc analysis of the subset of patients with well-deﬁned
steatohepatitis at baseline: 19% vs 8%, respectively
(P < .05). These rates of response are very close to those
obtained in the current trial in the ITT population and in the
subset with NAS  4 (all FLINT participants had an NAS 
4). In post-hoc analyses from the subgroup of patients with
well-deﬁned NASH in the PIVENS (Pioglitazone vs Vitamin E
vs Placebo for Treatment of Non-Diabetic Patients With
Nonalcoholic Steatohepatitis) trial, pioglitazone induced
resolution of steatohepatitis in 47% of patients (21% for
placebo; P ¼ .001) and vitamin E in 36% (P ¼ .05). Direct
comparisons between molecules are misleading in the
absence of head-to-head trials, and because of differences in
inclusion criteria and in deﬁnitions of histologic response.
Importantly, a detailed deﬁnition of “resolution of steato-
hepatitis” is not available from FLINT or PIVENS. In addi-
tion, there was no requirement for the absence of
“worsening of ﬁbrosis” when deﬁning resolution of NASH as
an end point for either PIVENS or FLINT, which further
limits comparisons between rates of response with the
GOLDEN-505 trial. Only large, phase 3 trials will provide
reliable estimates of treatment response for obeticholic acid
and elaﬁbranor, but what is clear so far is that a majority of
patients are nonresponders and that additional pharmaco-
logic strategies will be necessary to optimize the response
rate.
In conclusion, this randomized controlled trial pro-
vides evidence that pharmacologic modulation of the
PPARa/d nuclear receptors results in substantial histologic
improvement in NASH, including resolution of steatohepa-
titis and improvement of the cardiometabolic risk proﬁle,
with a favorable safety proﬁle. Larger phase 3 trials of ela-
ﬁbranor in the target population of patients with moderate
to severe NASH are warranted.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dx.doi.org/10.1053/
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Supplementary Figure 1.Overall improvement in liver histology in patients who achieved the primary outcome according
to the modiﬁed deﬁnition of response in the elaﬁbranor 120-mg arm. Results are expressed as mean values of changes from
baseline during treatment in responders (n ¼ 17) and nonresponders (n ¼ 61) to elaﬁbranor 120 mg. Error bars represent 95%
CIs. *P < .05; **P < .01; ***P < .001.
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Supplementary Figure 2. Changes from baseline in inﬂammatory markers (Sup2A) and in noninvasive scores of ﬁbrosis and
steatosis (Sup2B) in treatment groups in the per protocol analysis (n ¼ 237). Results are expressed as mean values of changes
from baseline during treatment with placebo (n ¼ 77), elaﬁbranor 80 mg (n ¼ 82) and elaﬁbranor 120 mg (n ¼ 78). Error bars
represent 95% CIs. *P < .05; **P < .01; ***P < .001 vs baseline. #P < .05; ##P < .01; ###P < .001 vs placebo.
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Supplementary Table 1.Reasons for Dropout From the Trial
(n ¼ 33 [12%])
Reason for dropout during the trial n (%)
Adverse events 17 (51.5)
Consent withdrawal 11 (33.3)
Lost to follow-up 1 (3)
Noncompliance 2 (6)
Protocol withdrawal criteria 2 (6)
Supplementary Table 2. Interaction Effect Between Treatment and bNAS in the ITT Population (n ¼ 274 patients) With
Protocol-Deﬁned and the Modiﬁed Deﬁnitions of the Primary Outcome
Elaﬁbranor dose
Protocol-deﬁned deﬁnition Modiﬁed deﬁnition
OR (95% CI) RR (95% CI) P (OR) OR (95% CI) RR (95% CI) P (OR)
80 mg 1.80 (0.853.82) 1.61 (0.882.92) .125 1.28 (0.572.86) 1.24 (0.642.40) .551
120 mg 2.63 (1.255.52) 2.09 (1.163.77) .012 2.76 (1.335.76) 2.23 (1.244.03) .007
RR, relative risk.
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Supplementary Table 3.Secondary Histologic End Points: Descriptive Analyses of Improvement in Histologic Lesions
According to Baseline NAS Severity in the ITT Population (n ¼ 274)
Variable Baseline severity (bNAS), n Placebo, % Elaﬁbranor, 80 mg, % Elaﬁbranor, 120 mg, %
NAS 2-point reduction
Severe (68), 90 23 28 40
Moderate (45), 144 20 20 27
Mild (3), 40 31 20 14
Steatosis
Severe (68), 90 10 10 33
Moderate (45), 144 27 24 22
Mild (3), 40 0 10 7
Hepatocyte ballooning
Severe (68), 90 16 34 40
Moderate (45), 144 29 31 33
Mild (3), 40 38 40 21
Lobular inﬂammation
Severe (68), 90 39 48 53
Moderate (45), 144 18 19 24
Mild (3), 40 44 10 14
Supplementary Table 4.Histologic Changes in Patients With Moderate/Severe NASH (bNAS 4) Randomized in Centers That
Included in Each Treatment Arm (n ¼ 120)
Variable
Placebo
(n ¼ 39)
Elaﬁbranor, 80 mg
(n ¼ 50)
Elaﬁbranor, 120 mg
(n ¼ 31)
P value (120 mg vs
placebo)
Resolution of NASH (without worsening of ﬁbrosis),a % 5 8 26 .02
Resolution of NASH (without worsening of ﬁbrosis),b % 5 18 29 .01
Decrease of NAS 2, % 21 18 48 .01
Mean change in NAS score 0.38 0.38 1.1 .02
Steatosisc
Patients with decrease of at least 1 point 18 14 35 .10
Change in score 0.03 0.10 0.13 .35
Hepatic ballooningc
Patients with decrease of at least 1 point 23 26 45 .02
Change in score 0.15 0.22 0.45 .01
Lobular inﬂammationc
Patients with decrease of at least 1 point 33 30 55 .05
Change in score 0.26 0.26 0.52 .10
aAccording to the modiﬁed deﬁnition of resolution of NASH without worsening of ﬁbrosis.
bAccording to the protocol-deﬁned primary outcome.
cAdjusted for baseline severity of steatosis, ballooning and inﬂammation, respectively, at baseline.
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Supplementary Table 5. Individual Data for Creatinine and Creatinine Clearance in Patients With Treatment-Associated
Increases in Serum Creatinine
ID (site/patient) Sex
Creatinine, mg/dL
Elaﬁbranor
treatment armV2 V3 V4 V5 V6 V7 V8
203/01 M 1.13 1.27 1.36 1.27 1.30 1.28 1.17 120 mg
302/04 F 0.93 1.16 1.17 1.14 1.17 1.17 1.08 80 mg
302/05 M 1.06 1.50 1.32 1.28 1.19 1.35 1.21 120 mg
302/06 M 0.89 0.90 1.16 1.09 1.02 1.09 1.20 120 mg
303/03 F 0.92 1.00 1.07 1.07 1.08 1.14 1.05 120 mg
902/05 M 1.38 1.64 1.53 1.67 2.02 0.00 1.59 120 mg
916/03 F 1.33 1.41 1.34 1.25 1.26 1.41 1.25 120 mg
Creatinine clearance, mL/min
V1 V2 V3 V4 V5 V6 V7 V8
203/01 M 60 60 59 55 59 58 59 60
302/04 F 60 60 48 47 49 47 47 52
302/05 M 60 60 47 55 57 60 53 60
302/06 M 60 60 60 60 60 60 60 60
303/03 F 60 60 56 52 52 51 48 53
902/05 M 57 52 43 46 42 33 — 44
916/03 F 58 50 46 49 53 53 46 53
F, female; M, male; V, protocol-deﬁned patient visits.
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